Botulinum Toxin Market size is anticipated to reach USD 10 Billion by the end of 2033, growing at a CAGR of 9% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of botulinum toxin was USD 4 Billion. The growth of the market can be attributed to the globally increasing proportion of the geriatric population, which is more prone to deal with numerous health and skin issues. Further, the rising demand for minimally invasive or noninvasive surgeries such as - glabellar lines, and chemical browlift treatments is estimated to propel market growth during the forecast period. As per the estimations, it is found that noninvasive treatments such as dermal fillers and botox rose by over 180% in the United States, and in 2018 more than 70% of U.S surgeons noted the increase in the use of injectables among people under 30 years.
In addition to these, factors that are believed to fuel the market growth of botulinum toxin include the rising ratio of people who are dealing with premature aging issues or photoaging, since the premature aging issue is such a significant factor that has been playing a pivotal role in the surging level of various kinds of cosmetic surgeries. Additionally, soaring investment by the major key players to enhance the research and development, coupled with growing expenditure for developing advanced healthcare infrastructure, and rising amendments in reimbursement policies to cover the botulinum procedures and injections are anticipated to present the potential for botulinum toxin market expansion over the projected period. Besides this, a worldwide surge in healthcare expenditure is also estimated to expand the market size of botulinum toxin in the coming years.
Growth Drivers
person is able to afford it. On the other hand, with rising disposable income, people are focusing more on how they look and are willing to spend on facial treatments. Botox costs about USD 10-15 per unit anywhere across the globe, and more than USD 400 for the full treatment. The rising adoption of minimally invasive procedures and the high willingness of people to spend on aesthetically looking
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~9% |
|
Base Year Market Size (2022) |
~ USD 4 Billion |
|
Forecast Year Market Size (2033) |
~ USD 10 Billion |
|
Regional Scope |
|
End-user (Hospitals, Dermatology Clinics, Spas, Cosmetic Centers)
The global botulinum toxin market is segmented and analyzed for demand and supply by end-user in hospitals, dermatology clinics, spas, and cosmetic centers. Amongst these four segments, the hospitals segment is anticipated to hold the largest market size by the end of 2033. The growth of this segment can be attributed to the increasing number of hospitals with advanced cases and facilities, followed by the rising awareness regarding aesthetic procedures in individuals. For instance, the number of hospitals in the United Kingdom has increased to nearly 29 per one million people in the year 2019. Moreover, a growing number of medical spas and cosmetic centers is another significant factor that is estimated to boost the growth of the market, as the surge in cosmetic centers and spas generate more traction in people to access beauty procedures. For instance, in the U.S. there are about 20,000 health and wellness spas as of 2022.
Product Type (Botulinum Toxin A, Botulinum Toxin B)
The global botulinum toxin market is also segmented and analyzed for demand and supply by product type into botulinum toxin A and botulinum toxin B. Out of these, the botulinum toxin A segment is expected to garner a significant share. The significant growth in this segment is backed by the escalating utilization of botulinum toxin A to treat headaches as of hypertension, chronic migraine, and several primary neurological diseases. In addition to these, the penetration of botulinum toxin A products has been growing in the wide range of aesthetic purposes, therefore, the proliferating demand for aesthetic beauty products is also anticipated to fuel the growth of the market during the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Product Type |
|
|
By Application |
|
|
By Gender |
|
|
By Age Group |
|
|
By End-User |
|
North American Market Forecast
The North American botulinum toxin market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed majorly to the increasing spending capacity of individuals, which has been fueling the urge to be more attractive and to use several aesthetic products to improve their physical beauty. For instance, the consumer spending capacity of U.S. people rose from -0.2% in July 2022 to 0.6% in July Sept 2022, as per the Bureau of Economic Analysis. Further, the rising number of cosmetic procedures to look beautiful, escalating adoption of facial injectables, and the rapid adoption of aesthetic procedures among individuals, are also anticipated to contribute to the market growth in the region. In addition to this, the growing advancements in medical and aesthetic procedures are some more factors that are estimated to propel market’s growth further throughout the forecast period in the region.
APAC Market Statistics
Whereas, the Asia Pacific botulinum toxin market is anticipated to witness a larger CAGR over the projected time frame on the back of the presence of a larger patient pool for minimally invasive surgeries, along with, increasing demand for botulinum toxins in the countries such as China, and Japan. Additionally, the highly growing beauty consciousness, coupled with the surge in wellness tourism, is elevating the number of spas, and cosmetic centers in the countries such as Korea, Thailand, Singapore, and so on. These are other significant factors that are projected to propel the growth of the market during the projected timeframe in the region. For instance, in 2018, the number of wellness spas in the Asia Pacific region reached approximately 93,565. Such an extraordinary boost in the count of wellness spas in this region is indicating a higher increase in the same over the coming years, which is projected to further drive market growth in the region.
Allergan, an AbbVie Inc. announced the U.S Food and Drug Administration (FDA) approval to expand the label of botox to include eight more muscles to treat adults with upper limb spasticity. The new approval was significant as it treated disabling neurological conditions influencing the quality of life of a patient.
Ipsen Group declared that Dysport, a clostridium botulinum type A toxin-haemagglutinin complex received the U.S. FDA. Dysport is the first UK botulinum toxin to get approved for pediatric spasticity therapy in upper and lower limbs.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?